

Alvespimycin (hydrochloride)

Catalog No: tcsc0162

Available Sizes

Size: 10mg

Size: 25mg

Size: 100mg

Size: 200mg

Specifications

CAS No:

467214-21-7

Formula:

 $\mathsf{C}_{32}\mathsf{H}_{49}\mathsf{CIN}_4\mathsf{O}_8$

Pathway:

Metabolic Enzyme/Protease;Cell Cycle/DNA Damage

Target: HSP;HSP

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 50 mg/mL (76.55 mM)

Alternative Names:

17-DMAG hydrochloride;KOS-1022;BMS 826476

Observed Molecular Weight: 653.21

Copyright 2021 Taiclone Biotech Corp.



Product Description

Alvespimycin hydrochloride is a potent inhibitor of **Hsp90**, binding to Hsp90 with **EC**₅₀ of 62±29 nM.

IC50 & Target: EC50: 62 nM±29 nM (Hsp90)^[1]

In Vitro: Alvespimycin (17-DMAG) hydrochloride inhibits the growth of the human cancer cell lines SKBR3 and SKOV3, which overexpress Hsp90 client protein Her2, and causes down-regulation of Her2 as well as induction of Hsp70 consistent with Hsp90 inhibition, for Her2 degradation with EC_{50} of 8±4 nM and 46±24 nM in SKBR3 and SKOV3 cells, respectively; for Hsp70 induction with EC_{50} of 4±2 nM and 14±7 nM in SKBR3 and SKOV3 cells, respectively^[1]. Compared with the vehicle control, 17-DMAG exerts dose-dependent apoptosis (P[2].

In Vivo: The tumors are grown for two months before the start of i.p. injections every four days over one month with 0, 50, 100 and 200 mg/kg dipalmitoyl-radicicol or 0, 5, 10 and 20 mg/kg 17-DMAG. Despite sample heterogeneity, the HSP90 inhibitor-treated animals have significantly lower tumour volumes than the vehicle control-treated animals. HSP90 inhibitors have been shown to cause liver toxicity in an animal model of gastrointestinal cancer. Nevertheless, the reduction in tumor size using dipalmitoyl-radicicol is statistically significant at 100 mg/kg, while 17-DMAG at either 10 or 20 mg/kg elicited a significant reduction in tumor size [3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.